RNA Targeting Small Molecule Drug Discovery Market Overview:
The RNA Targeting Small Molecule Drug Discovery Market size was valued at USD 1,723 million in 2024 and is anticipated to reach USD 8852.98 million by 2032, at a CAGR of 22.7 % during the forecast period.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
RNA Targeting Small Molecule Drug Discovery Market Size 2024
USD 1,723 million
RNA Targeting Small Molecule Drug Discovery Market, CAGR
22.7%
RNA Targeting Small Molecule Drug Discovery Market Size 2032
USD 8852.98 million
RNA Targeting Small Molecule Drug Discovery Market Insights:
North America accounts for 42.6% share, Europe holds 28.4%, and Asia-Pacific represents 22.1% of the market, supported by advanced biopharmaceutical infrastructure, strong public–private research funding, early technology adoption, and deep expertise in RNA biology and medicinal chemistry.
Asia-Pacific is the fastest-growing region with a 22.1% share, supported by accelerating biotechnology investments, government funding in genomics, expanding discovery platforms, and increasing participation from China, Japan, and South Korea in advanced RNA drug research.
By indication, oncology dominates with 46.8% share, driven by RNA dysregulation in cancer pathways, strong biomarker availability, and high clinical trial activity focused on resistant and refractory tumors.
By end-user, pharmaceutical companies hold 52.3% share, supported by strong capital resources, integrated discovery-to-commercialization capabilities, and growing adoption of RNA-focused platforms to diversify therapeutic pipelines.
RNA Targeting Small Molecule Drug Discovery Market Drivers:
Expanding Recognition of RNA as a Drug-Relevant Therapeutic Target Beyond Proteins
The RNA Targeting Small Molecule Drug Discovery Market gains momentum from expanding scientific recognition of RNA as a viable therapeutic target. Many diseases remain insufficiently addressed by protein-centric drugs, creating demand for alternative molecular intervention strategies. RNA structures regulate gene expression, splicing, and translation, which positions them as high-value control points in disease pathways. It benefits from growing experimental evidence that small molecules can bind RNA with functional selectivity. This validation strengthens confidence among drug developers and investors.
For instance, PTC Therapeutics developed risdiplam, which modulates SMN2 splicing in spinal muscular atrophy by targeting RNA structures. This achieved up to 7-fold increase in full-length SMN protein production in preclinical models.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research Inc.!
Advancements in RNA Structural Biology and Molecular Characterization Technologies
Rapid progress in RNA structural biology supports market expansion by enabling rational drug design. High-resolution imaging, cryo-electron microscopy, and advanced spectroscopy improve understanding of RNA folding and binding pockets. These tools reduce discovery risk by guiding structure-based screening and lead optimization. It gains efficiency from better target validation and mechanistic clarity. Improved predictability shortens development timelines and supports scalable discovery programs.
For instance, SLAC and Stanford researchers utilized cryogenic electron microscopy to image large protein-free RNA complexes, revealing multi-strand assemblies previously unknown without protein support.
Rising Investment in Precision Medicine and Hard-to-Treat Disease Areas
Pharmaceutical and biotechnology companies increase investment to address cancers, rare genetic disorders, and infectious diseases with unmet therapeutic needs. RNA-focused small molecules offer precision modulation without permanent genetic alteration. It aligns with precision medicine strategies that prioritize target specificity and controlled pharmacology. Growing venture capital funding supports early-stage platforms and translational research. Strong pipeline activity reinforces long-term commercial potential.
Strengthening Collaborative Ecosystems Between Industry and Academic Research Centers
Collaborations between academia, biotech firms, and pharmaceutical companies accelerate innovation across discovery pipelines. Academic laboratories provide foundational RNA biology insights that inform industrial drug design efforts. It benefits from shared data, specialized expertise, and access to proprietary screening platforms. Strategic partnerships reduce development risk and resource duplication. This ecosystem approach sustains steady advancement from discovery to clinical validation.
RNA Targeting Small Molecule Drug Discovery Market Trends:
Integration of Artificial Intelligence and Structure-Based Design in RNA-Focused Drug Discovery Pipelines
The RNA Targeting Small Molecule Drug Discovery Market reflects a clear shift toward artificial intelligence–enabled discovery platforms. Drug developers deploy machine learning to predict RNA folding, ligand affinity, and off-target interactions with higher precision. It benefits from AI-driven virtual screening that reduces experimental burden and improves hit identification rates. Structure-based design frameworks support selective binding to complex RNA motifs that were previously inaccessible. Companies pair computational chemistry with biophysical validation to strengthen lead quality. This trend improves reproducibility and scalability across early discovery programs.
For instance, Serna Bio employs AI-driven platforms to define precise RNA-small molecule interactions, achieving hit rates improved by over 5-fold compared to traditional screening in their oncology programs.
Expansion of Clinical Translation and Modality Convergence Across Therapeutic Areas
The RNA Targeting Small Molecule Drug Discovery Market shows growing emphasis on advancing candidates from discovery into clinical evaluation. Developers focus on optimizing pharmacokinetics, oral bioavailability, and tissue penetration to enhance therapeutic viability. It increasingly converges with other RNA-focused modalities such as antisense and RNA interference through combination strategies. Oncology and rare disease pipelines dominate translational activity due to strong biomarker alignment. Regulatory agencies provide clearer guidance on RNA-based therapeutics, which supports development confidence. This shift reinforces commercial readiness and long-term adoption across therapeutic portfolios.
For Instance, Skyhawk Therapeutics advanced SKY-0515 into a Phase 1 clinical trial for the treatment of Huntington’s disease.
RNA Targeting Small Molecule Drug Discovery Market Challenges Analysis:
Structural Complexity and Selectivity Constraints in RNA–Small Molecule Interactions
The RNA Targeting Small Molecule Drug Discovery Market faces significant challenges due to the structural flexibility and dynamic nature of RNA. Many RNA targets adopt multiple conformations, which complicates reliable binding prediction. It struggles with achieving high selectivity because similar structural motifs appear across different RNA species. Limited understanding of long-range RNA folding reduces confidence in target validation. Off-target interactions raise safety concerns and increase development risk. These factors slow lead optimization and increase attrition during early discovery phases.
Translational Uncertainty and Regulatory Pathway Ambiguity Across Development Stages
The RNA Targeting Small Molecule Drug Discovery Market encounters hurdles during translation from discovery to clinical application. Preclinical models often fail to fully reflect human RNA biology and disease relevance. It faces uncertainty in dose optimization and biomarker selection due to limited clinical precedent. Regulatory frameworks for RNA-targeted small molecules continue to evolve, which creates approval complexity. Extended validation timelines elevate development costs. These challenges constrain pipeline acceleration and commercial scalability.
RNA Targeting Small Molecule Drug Discovery Market Opportunities:
Unlocking Therapeutic Potential Across Undrugged and Genetically Driven Disease Targets
The RNA Targeting Small Molecule Drug Discovery Market presents strong opportunity through access to disease pathways that remain unreachable by protein-based therapies. Many genetic disorders, cancers, and viral diseases depend on RNA-mediated regulation. It enables reversible and selective modulation without permanent genomic alteration. Growing availability of RNA target databases improves prioritization and discovery success. Pharmaceutical pipelines seek differentiated assets with novel mechanisms of action. This shift supports sustained demand for RNA-focused small molecule programs.
Platform Expansion and Strategic Commercial Partnerships to Accelerate Scale
The RNA Targeting Small Molecule Drug Discovery Market benefits from platform-based discovery models that support multi-target scalability. Biotech companies develop proprietary libraries and screening systems tailored to RNA structures. It attracts partnerships with large pharmaceutical firms that seek external innovation. Licensing and co-development agreements reduce capital burden and enhance market reach. Expanding precision medicine strategies favor adaptable discovery platforms. These factors create long-term growth pathways and commercial expansion potential.
RNA Targeting Small Molecule Drug Discovery Market Segmentation Analysis:
By Indication: Oncology, Rare Genetic Disorders, Infectious Diseases, Neurological Disorders
The RNA Targeting Small Molecule Drug Discovery Market shows strong differentiation across indication-based segments due to varied disease biology and unmet needs. Oncology leads this segment, supported by the critical role of RNA dysregulation in tumor growth, resistance pathways, and gene expression control. It benefits from strong biomarker availability and higher R&D funding intensity. Rare genetic disorders represent a high-growth segment because RNA modulation enables precision correction of disease-causing transcripts. Infectious diseases gain traction through RNA-directed inhibition of viral replication, while neurological disorders progress steadily with improved central nervous system penetration strategies.
For Instance, Novartis advanced branaplam (LMI070), a small molecule targeting SMN2 splicing RNA in spinal muscular atrophy (SMA) models, achieving a significant increase (e.g., several-fold or dose-dependent) in full-length SMN protein production in preclinical SMA mouse models and patient-derived cells.
By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes
The RNA Targeting Small Molecule Drug Discovery Market demonstrates clear segmentation across end-user categories based on discovery capability and commercialization focus. Pharmaceutical companies dominate adoption due to strong financial resources, late-stage development expertise, and global regulatory experience. It supports pipeline diversification through internal RNA-focused programs and external licensing. Biotechnology companies drive early innovation by developing specialized RNA discovery platforms and novel screening libraries. Academic and research institutes play a critical role in target discovery and mechanistic validation, which strengthens translational pipelines and supports long-term market expansion.
For instance, Skyhawk Therapeutics partnered with Ipsen in April 2024 to discover and develop novel RNA-targeting small molecules for rare neurological diseases.
Segmentations:
By Indication
Oncology
Rare Genetic Disorders
Infectious Diseases
Neurological Disorders
Metabolic Disorders
By End-User
Pharmaceutical Companies
Biotechnology Companies
Academic and Research Institutes
Contract Research Organizations
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
South Korea
South-east Asia
Rest of Asia Pacific
Latin America
Brazil
Argentina
Rest of Latin America
Middle East & Africa
GCC Countries
South Africa
Rest of the Middle East and Africa
Regional Analysis:
North America Leadership Supported by Advanced Research Infrastructure and Capital Availability
The RNA Targeting Small Molecule Drug Discovery Market holds its strongest position in North America due to a mature biopharmaceutical ecosystem. The region benefits from deep expertise in RNA biology, medicinal chemistry, and translational science. It attracts substantial venture capital and public funding that support early discovery and clinical advancement. Strong presence of large pharmaceutical companies accelerates platform validation and commercialization. Regulatory agencies provide structured guidance for novel RNA-based therapeutics. High collaboration intensity between academia and industry sustains innovation velocity.
Europe Expansion Driven by Public–Private Research Programs and Regulatory Alignment
The RNA Targeting Small Molecule Drug Discovery Market demonstrates steady growth across Europe through coordinated research initiatives. Government-backed funding programs support RNA-focused drug discovery and rare disease research. It benefits from harmonized regulatory standards that reduce development complexity across countries. Strong academic institutions contribute foundational RNA science and target validation. Pharmaceutical hubs in Germany, the United Kingdom, and France strengthen translational output. Cross-border partnerships improve resource efficiency and knowledge exchange.
Asia-Pacific Growth Accelerated by Biotechnology Investment and Genomics Initiatives
The RNA Targeting Small Molecule Drug Discovery Market records the fastest growth rate in the Asia-Pacific region. Rising government investment in genomics and precision medicine strengthens discovery infrastructure. It gains momentum from expanding biotech clusters in China, Japan, South Korea, and India. Local companies increase participation in early-stage RNA research and licensing activity. Improving regulatory clarity supports clinical trial initiation. This regional expansion enhances global pipeline diversity and long-term market scale.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The RNA Targeting Small Molecule Drug Discovery Market features a concentrated yet rapidly evolving competitive landscape driven by scientific differentiation and platform depth. Established pharmaceutical companies compete through internal RNA discovery programs, strong medicinal chemistry capabilities, and late-stage development expertise. It favors players that demonstrate validated RNA-binding libraries, robust target selection strategies, and translational proof of concept. Biotechnology firms strengthen competition by advancing proprietary RNA-focused platforms and first-in-class mechanisms of action. Strategic partnerships and licensing agreements remain central to competitive positioning, enabling access to capital, clinical infrastructure, and global commercialization channels. Companies emphasize intellectual property protection around RNA motifs, screening technologies, and structure-based design methods. Competitive advantage increasingly depends on clinical progression speed, portfolio breadth across indications, and the ability to reduce off-target risk while maintaining therapeutic selectivity.
Recent Developments:
In April 2025, F. Hoffmann-La Roche Ltd announced a USD 50 billion investment in the United States over five years, including new R&D sites, manufacturing facilities, and over 12,000 jobs.
In October 2025, F. Hoffmann-La Roche Ltd reported strong nine-month sales growth of 7% (CER), raised full-year earnings outlook, and highlighted pipeline progress with ten transformative medicines entering final development phases.
Report Coverage:
The research report offers an in-depth analysis based on Indication, End-User, and Region. It details leading Market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current Market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven Market expansion in recent years. The report also explores Market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on Market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the Market.
Future Outlook:
The RNA Targeting Small Molecule Drug Discovery Market will progress from exploratory research toward validated clinical pipelines across multiple therapeutic areas.
Drug developers will prioritize RNA targets linked to high unmet medical needs, particularly in oncology and rare genetic disorders.
Advances in RNA structure elucidation will improve target confidence and support more selective small molecule design.
Artificial intelligence tools will become standard across discovery workflows, enhancing hit identification and lead optimization efficiency.
Pharmaceutical companies will expand internal RNA-focused platforms to diversify pipelines beyond protein-centric approaches.
Biotechnology firms will strengthen their role as innovation drivers through specialized RNA libraries and discovery technologies.
Strategic partnerships will increase, supporting shared risk models and faster translation into clinical development.
Regulatory agencies will refine guidance frameworks for RNA-targeted small molecules, improving development clarity.
Improved delivery and pharmacokinetic profiles will enhance tissue specificity and therapeutic durability.
Long-term adoption will depend on clinical success, safety validation, and differentiation from existing RNA-based modalities.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Market Introduction
4.1. Overview of RNA Targeting Small Molecule Drug Discovery
4.2. Key Industry Trends
4.3. Technological Advancements
4.4. Regulatory Landscape 5. Global RNA Targeting Small Molecule Drug Discovery Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Indication
6.1. Oncology
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Rare Genetic Disorders
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Infectious Diseases
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity
6.4. Neurological Disorders
6.4.1. Market Trends
6.4.2. Market Forecast
6.4.3. Revenue Share
6.4.4. Revenue Growth Opportunity
6.5. Metabolic Disorders
6.5.1. Market Trends
6.5.2. Market Forecast
6.5.3. Revenue Share
6.5.4. Revenue Growth Opportunity 7. Market Breakup by End-User
7.1. Pharmaceutical Companies
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. Biotechnology Companies
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. Academic and Research Institutes
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. Contract Research Organizations
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity
7.5. Government Research Organizations
7.6. Healthcare Institutions
7.7. Drug Discovery Startups
7.8. Translational Research Centers
7.9. Others 8. Market Breakup by Molecule Type
8.1. Small Molecule RNA Binders
8.2. RNA Splicing Modulators
8.3. RNA Structure Targeting Molecules
8.4. RNA Translation Inhibitors
8.5. RNA Stability Modulators
8.6. Others 9. Market Breakup by Region
9.1. North America
9.1.1. United States
9.1.1.1. Market Trends
9.1.1.2. Market Forecast
9.1.2. Canada
9.2. Asia-Pacific
9.2.1. China
9.2.2. Japan
9.2.3. India
9.2.4. South Korea
9.2.5. Australia
9.2.6. Indonesia
9.2.7. Others
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. United Kingdom
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Others
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Others
9.5. Middle East and Africa
9.5.1. Market Trends
9.5.2. Market Breakup by Country
9.5.3. Market Forecast 10. SWOT Analysis
10.1. Overview
10.2. Strengths
10.3. Weaknesses
10.4. Opportunities
10.5. Threats 11. Value Chain Analysis 12. Porter’s Five Forces Analysis
12.1. Overview
12.2. Bargaining Power of Buyers
12.3. Bargaining Power of Suppliers
12.4. Degree of Competition
12.5. Threat of New Entrants
12.6. Threat of Substitutes 13. Price Analysis 14. Competitive Landscape
14.1. Market Structure
14.2. Key Players
14.3. Profiles of Key Players
14.3.1. Accent Therapeutics
14.3.2. Anima Biotech Inc.
14.3.3. Arrakis Therapeutics
14.3.4. AstraZeneca
14.3.5. Epics Therapeutics
14.3.6. Expansion Therapeutics
14.3.7. F. Hoffmann-La Roche Ltd
14.3.8. PTC Therapeutics, Inc.
14.3.9. Ribometrix
14.3.10. Les Laboratoires Servier
14.3.11. Skyhawk Therapeutics 15. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions
What is the current market size of the RNA Targeting Small Molecule Drug Discovery Market, and what is its projected size by 2032?
The RNA Targeting Small Molecule Drug Discovery Market was valued at USD 1,723 million in 2024. It is projected to reach USD 8,852.98 million by 2032, reflecting strong expansion driven by increasing scientific validation, expanding clinical pipelines, and rising pharmaceutical R&D investments.
At what Compound Annual Growth Rate (CAGR) is the market expected to grow between 2024 and 2032?
The market is anticipated to grow at a robust CAGR of 22.7% during the forecast period from 2024 to 2032, supported by rapid advances in RNA biology, computational chemistry, and precision medicine strategies.
Which segment held the largest share of the market in 2024?
By indication, oncology dominated the market in 2024 with a 46.8% share, driven by the central role of RNA dysregulation in cancer progression, strong biomarker availability, and high clinical trial activity in resistant and refractory tumors.
What are the key factors driving the growth of the RNA Targeting Small Molecule Drug Discovery Market?
Key growth drivers include expanding recognition of RNA as a druggable therapeutic target beyond proteins, advancements in RNA structural biology and molecular characterization technologies, rising investment in precision medicine and hard-to-treat diseases, and strengthening collaborations between pharmaceutical companies, biotechnology firms, and academic research institutes.
Who are the leading companies operating in the RNA Targeting Small Molecule Drug Discovery Market?
Major players in the market include Accent Therapeutics, Anima Biotech Inc., Arrakis Therapeutics, AstraZeneca, Expansion Therapeutics, F. Hoffmann-La Roche Ltd, PTC Therapeutics, Inc., Ribometrix, Les Laboratoires Servier, and Skyhawk Therapeutics, among others.
Which region held the largest share of the market in 2024?
North America commanded the largest share of the RNA Targeting Small Molecule Drug Discovery Market in 2024, accounting for 42.6% of global revenue. This leadership is supported by advanced biopharmaceutical R&D infrastructure, strong venture capital funding, and early adoption of RNA-focused drug discovery technologies.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The Prostatic Catheter Market size was valued at USD 199 million in 2024 and is anticipated to reach USD 309.44 million by 2032, at a CAGR of 5.7% during the forecast period.
The Rapid Microbiology Tests Market size was valued at USD 6,178 million in 2024 and is anticipated to reach USD 10496.15 million by 2032, at a CAGR of 6.85 % during the forecast period.
The Reversible Airway Diseases Treatment Market size was valued at USD 85,518 million in 2024 and is anticipated to reach USD 143671.9 million by 2032, at a CAGR of 6.7 % during the forecast period.
The Rare Disease Clinical Trials Market size was valued at USD 12,949 million in 2024 and is anticipated to reach USD 21592.72 million by 2032, at a CAGR of 6.6 % during the forecast period.
The Rare Disease Genetic Testing Market size was valued at USD 1,197 million in 2024 and is anticipated to reach USD 3703.24 million by 2032, at a CAGR of 15.16 % during the forecast period.
The RAS Mutation Detection Kit Market size was valued at USD 107 million in 2024 and is anticipated to reach USD 188.53 million by 2032, at a CAGR of 7.4 % during the forecast period.
The Precision Medicine Market size was valued at USD 91,298 million in 2024 and is anticipated to reach USD 204409.6 million by 2032, at a CAGR of 10.6 % during the forecast period.
The Postpartum Depression Market size was valued at USD 68 million in 2024 and is anticipated to reach USD 815.92 million by 2032, at a CAGR of 36.5% during the forecast period.
The Next-Generation Centrifuge Market size was valued at USD 1,175 million in 2024 and is anticipated to reach USD 1709.14 million by 2032, at a CAGR of 4.8 % during the forecast period.
The Metastatic Melanoma Cancer Diagnostics Market size was valued at USD 3,622 million in 2024 and is anticipated to reach USD 6364.41 million by 2032, at a CAGR of 7.3 % during the forecast period.
The Personalized LASIK Surgery Market size was valued at USD 3,992 million in 2024 and is anticipated to reach USD 5764.8 million by 2032, at a CAGR of 4.7% during the forecast period (2024-2032).
The Neonatal Hearing Screening Devices Market size was valued at USD 410 million in 2024 and is anticipated to reach USD 644.07 million by 2032, at a CAGR of 5.8 % during the forecast period.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
